Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

Fig. 2

Assessment of disease activity and treatment response in PANGAEA 2.0. In the first study phase disease activity will be assessed according to Lublin et al. [7]. Disease active patients who switch to fingolimod are subjected to a 3-year observation period. Disease progression and treatment response will be assessed by using the modified Rio score [8] (figure adapted from [10]). Definition of active disease by Lublin et al. 2014 and evaluation of disease progression and treatment response by the modified Rio Score

Back to article page